Table 3.

Oxford scores related to clinical outcomes in multivariate analyses including treatment with immunosuppression in IgA nephropathy

Clinical Outcome After Immunosuppressiona	Clinical Outcome	No. of Papers	No. of Analyses	No. of Analyses with C	M	E	S	T	C	None of MESTC
Improved	ESKD	4	7b	3	0	0	2	6	1	0
	ESKD with another end point	2	2	2	0	1	0	1	1	1
	Rate of eGFR decline	1	1	1	0	0	0	1	0	0
	Other	3	3	3	0	0	0	0	1	2
Total: Improved		10	13b	9	0	1	2	8	3	3
Not improved	ESKD	2c	2	2	0	0	0	2	0	0
	ESKD with another end point	4	4	3	1	0	1	3	1	0
	Other	2c	2	2	0	0	0	0	0	2
Total: Not improved		8c	8	7	1	0	1	5	1	2
Worse: Total	ESKD	1	1	1	0	0	0	1	0	0
Not said	ESKD	2	2	2	0	0	1	1	0	1
	ESKD with another end point	2	2	1	0	0	0	1	0	1
	Other	3	4d	2	3	0	1	1	0	1
Total: Not said		7	8d	5	3	0	2	3	0	3
Overall total		26c	30b,d	22	4	1	5	17	4	8

M, mesangial cellularity; E, endothelial hypercellularity; S, segmental sclerosis/capsular adhesion; T, tubular atrophy/interstitial fibrosis; C, (fibro) cellular crescents.

^aDetails in Supplemental Table 5.

^bFour analyses in one paper.

^cTwo outcomes in one paper.

^dTwo analyses in one paper.